Clinical Pharmacology of Cannabinoid Therapeutics: Drug Interactions and Side Effects

Cascorbi, Ingolf

doi:10.1002/cpt.3037

Cited by 1 publication

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Extensive clinical studies have highlighted the signi cant role of cannabinoids (CB) in various medical conditions, including in ammatory, autoimmune, cardiovascular, gastrointestinal, liver, kidney, lung diseases, neurodegenerative and psychiatric disorders, chronic pain, and cancer [5][6][7][8][9][10]. These ndings have led to planned clinical trials to assess the e cacy and safety of phytocannabinoids.…”

Section: Introductionmentioning

confidence: 99%

The monoacylglycerol lipase inhibitor JZL184 and ARDS: Differential effects in direct and indirect rat models

ELMA,

CAN,

FERAH

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose Acute respiratory distress syndrome (ARDS) leads to high morbidity and mortality, with limited pharmacological treatments and a reliance on supportive therapies. Recent evidence suggests cannabinoids may offer protective and therapeutic benefits against tissue damage, including lung pathologies. While cannabinoids' positive impacts on lung pathologies are known, their specific effects on ARDS mechanisms have not been thoroughly examined. The study purposes to explore the protective effects of cannabinoids on lung injury in direct and indirect ARDS models, focusing on differences in pathophysiological mechanisms. Methods Rats received lipopolysaccharide (LPS, 5 mg/kg, intratracheally) for direct models or alpha-naphthylthiourea (ANTU, 10 mg/kg, intraperitoneally) for indirect models. Endocannabinoid degrading enzyme, MAGL inhibitor JZL184 (10 mg/kg, i.p.) was administered 30 min before LPS or ANTU. After 24 hours of LPS and 4 hours of ANTU applications lung tissue samples were collected. Results In the LPS group, significant epithelial damage and intense NF-κB and caspase-3 staining around the bronchiolar epithelium were observed, with JZL184 effectively reducing inflammation and these markers in the area. In the ANTU group, the damage was more focused on the endothelium with similar increases in NF-κB and caspase-3 staining in the alveolar walls, where JZL184 also decreased inflammation and markers intensity. Overall, JZL184 showed a protective effect against inflammation, apoptosis, and tissue damage in lung injuries, highlighting the therapeutic potential of MAGL inhibition in ARDS treatment, with variations in effects depending on the injury model. Conclusion MAGL inhibition showed model-specific benefits against ARDS-related inflammation, apoptosis, and tissue damage, highlighting its therapeutic potential.

show abstract